Farther Finance Advisors LLC Buys 4,091 Shares of Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX)

Farther Finance Advisors LLC boosted its position in Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) by 176.9% in the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 6,404 shares of the company’s stock after buying an additional 4,091 shares during the period. Farther Finance Advisors LLC’s holdings in Recursion Pharmaceuticals were worth $42,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also added to or reduced their stakes in RXRX. Green Alpha Advisors LLC grew its stake in Recursion Pharmaceuticals by 2.9% in the third quarter. Green Alpha Advisors LLC now owns 64,799 shares of the company’s stock valued at $427,000 after acquiring an additional 1,800 shares during the period. Interchange Capital Partners LLC grew its position in Recursion Pharmaceuticals by 7.3% in the 2nd quarter. Interchange Capital Partners LLC now owns 34,580 shares of the company’s stock valued at $268,000 after purchasing an additional 2,349 shares during the period. Amalgamated Bank increased its stake in Recursion Pharmaceuticals by 52.4% during the 2nd quarter. Amalgamated Bank now owns 7,152 shares of the company’s stock valued at $54,000 after purchasing an additional 2,459 shares in the last quarter. Victory Capital Management Inc. increased its stake in Recursion Pharmaceuticals by 13.5% during the 2nd quarter. Victory Capital Management Inc. now owns 21,891 shares of the company’s stock valued at $164,000 after purchasing an additional 2,598 shares in the last quarter. Finally, Marathon Capital Management raised its holdings in Recursion Pharmaceuticals by 1.6% during the second quarter. Marathon Capital Management now owns 175,220 shares of the company’s stock worth $1,314,000 after buying an additional 2,675 shares during the last quarter. 89.06% of the stock is owned by institutional investors.

Recursion Pharmaceuticals Stock Down 5.6 %

Recursion Pharmaceuticals stock opened at $6.91 on Friday. Recursion Pharmaceuticals, Inc. has a fifty-two week low of $5.89 and a fifty-two week high of $15.74. The company has a debt-to-equity ratio of 0.04, a quick ratio of 4.35 and a current ratio of 4.35. The firm’s 50-day simple moving average is $6.64 and its 200 day simple moving average is $7.62. The stock has a market cap of $1.94 billion, a PE ratio of -4.78 and a beta of 0.81.

Recursion Pharmaceuticals (NASDAQ:RXRX) last announced its earnings results on Wednesday, November 6th. The company reported ($0.34) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.33) by ($0.01). The business had revenue of $26.08 million during the quarter, compared to analysts’ expectations of $12.62 million. Recursion Pharmaceuticals had a negative return on equity of 76.56% and a negative net margin of 579.52%. Recursion Pharmaceuticals’s quarterly revenue was up 147.6% on a year-over-year basis. During the same quarter in the previous year, the firm earned ($0.43) EPS. Research analysts predict that Recursion Pharmaceuticals, Inc. will post -1.56 EPS for the current fiscal year.

Insider Activity

In other news, CEO Christopher Gibson sold 20,000 shares of the stock in a transaction that occurred on Wednesday, September 4th. The shares were sold at an average price of $6.04, for a total transaction of $120,800.00. Following the completion of the transaction, the chief executive officer now directly owns 762,656 shares of the company’s stock, valued at $4,606,442.24. This represents a 2.56 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Blake Borgeson sold 11,447 shares of Recursion Pharmaceuticals stock in a transaction that occurred on Tuesday, August 20th. The stock was sold at an average price of $7.12, for a total transaction of $81,502.64. Following the completion of the sale, the director now directly owns 7,132,769 shares in the company, valued at $50,785,315.28. This trade represents a 0.16 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 183,129 shares of company stock valued at $1,214,974 in the last ninety days. 15.75% of the stock is currently owned by insiders.

Analysts Set New Price Targets

A number of brokerages have recently issued reports on RXRX. Jefferies Financial Group reduced their price objective on shares of Recursion Pharmaceuticals from $8.00 to $6.00 and set a “hold” rating for the company in a report on Tuesday, September 3rd. Needham & Company LLC reiterated a “buy” rating and set a $11.00 price target on shares of Recursion Pharmaceuticals in a research note on Thursday, November 7th. Finally, Leerink Partners decreased their price objective on Recursion Pharmaceuticals from $9.00 to $8.00 and set a “market perform” rating for the company in a report on Tuesday, September 3rd. Three equities research analysts have rated the stock with a hold rating and two have issued a buy rating to the company. According to data from MarketBeat.com, Recursion Pharmaceuticals presently has an average rating of “Hold” and a consensus price target of $9.25.

Recursion Pharmaceuticals Profile

Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers.